Overview
Xeroderma pigmentosum complementation group B (XP-B) is an extremely rare autosomal recessive disorder caused by mutations in the ERCC3 (XPB) gene, which encodes a DNA helicase essential for nucleotide excision repair (NER) and transcription. This Orphanet entry (276252) is marked as OBSOLETE, meaning it has been reclassified or merged into other clinical entities. Mutations in the ERCC3/XPB gene can give rise to a spectrum of overlapping phenotypes, including xeroderma pigmentosum (XP), XP combined with Cockayne syndrome (XP/CS), and trichothiodystrophy (TTD). Because of this phenotypic variability, the complementation group B designation has been reorganized under these broader diagnostic categories rather than maintained as a standalone entity. Classically, patients with XP-B-related disease present with extreme sensitivity to ultraviolet (UV) radiation, leading to severe sunburn reactions, freckling, and a markedly increased risk of skin cancers at a young age. The skin, eyes, and nervous system are the primary body systems affected. Ocular manifestations include photophobia, keratitis, and potential corneal opacification. Progressive neurological degeneration, including sensorineural hearing loss, cognitive decline, and peripheral neuropathy, may occur, particularly in patients with combined XP/CS features. Some patients also exhibit growth failure and characteristic facial features associated with Cockayne syndrome. There is no cure for XP-B-related conditions. Management is centered on rigorous UV protection, including avoidance of sunlight, use of protective clothing, UV-filtering eyewear, and regular dermatologic surveillance for early detection and treatment of skin cancers. Neurological and developmental complications require multidisciplinary supportive care. Patients should be referred to specialized centers experienced in managing DNA repair disorders for optimal long-term follow-up.
Also known as:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Xeroderma pigmentosum complementation group B.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Xeroderma pigmentosum complementation group B at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Xeroderma pigmentosum complementation group B.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Xeroderma pigmentosum complementation group B.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Xeroderma pigmentosum complementation group B.
Start the conversation →Latest news about OBSOLETE: Xeroderma pigmentosum complementation group B
No recent news articles for OBSOLETE: Xeroderma pigmentosum complementation group B.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about OBSOLETE: Xeroderma pigmentosum complementation group B
What is OBSOLETE: Xeroderma pigmentosum complementation group B?
Xeroderma pigmentosum complementation group B (XP-B) is an extremely rare autosomal recessive disorder caused by mutations in the ERCC3 (XPB) gene, which encodes a DNA helicase essential for nucleotide excision repair (NER) and transcription. This Orphanet entry (276252) is marked as OBSOLETE, meaning it has been reclassified or merged into other clinical entities. Mutations in the ERCC3/XPB gene can give rise to a spectrum of overlapping phenotypes, including xeroderma pigmentosum (XP), XP combined with Cockayne syndrome (XP/CS), and trichothiodystrophy (TTD). Because of this phenotypic varia
How is OBSOLETE: Xeroderma pigmentosum complementation group B inherited?
OBSOLETE: Xeroderma pigmentosum complementation group B follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Xeroderma pigmentosum complementation group B typically begin?
Typical onset of OBSOLETE: Xeroderma pigmentosum complementation group B is childhood. Age of onset can vary across affected individuals.